Our broad portfolio consists of multiplex panels that allow you to choose, within the panel, analytes that best meet your needs. On a separate tab you can choose the premixed cytokine format or a single plex kit.
Cell Signaling Kits & MAPmates™
Choose fixed kits that allow you to explore entire pathways or processes. Or design your own kits by choosing single plex MAPmates™, following the provided guidelines.
The following MAPmates™ should not be plexed together:
-MAPmates™ that require a different assay buffer
-Phospho-specific and total MAPmate™ pairs, e.g. total GSK3β and GSK3β (Ser 9)
-PanTyr and site-specific MAPmates™, e.g. Phospho-EGF Receptor and phospho-STAT1 (Tyr701)
-More than 1 phospho-MAPmate™ for a single target (Akt, STAT3)
-GAPDH and β-Tubulin cannot be plexed with kits or MAPmates™ containing panTyr
.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Select A Species, Panel Type, Kit or Sample Type
To begin designing your MILLIPLEX® MAP kit select a species, a panel type or kit of interest.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Species
Panel Type
Selected Kit
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
96-Well Plate
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
Add Additional Reagents (Buffer and Detection Kit is required for use with MAPmates)
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Space Saver Option Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
This item has been added to favorites.
The Product Has Been Added To Your Cart
You can now customize another kit, choose a premixed kit, check out or close the ordering tool.
LC3 precursors are proteolytically processed to form LC3-I, which is diffusely distributed in the cytosol. Upon initiation of autophagy, the C-terminal glycine of LC3-I is modified by addition of a phosphatidylethanolamine (PE) to form LC3-II, which translocates rapidly to nascent autophagosomes in a punctate distribution.
However, detecting and interpreting the relative amounts of LC3-I and LC3-II in standard assay methods can be complicated. When LC3 is immunochemically detected by Western Blotting following SDS-polyacrylamide gel electrophoresis, LC3-II typically appears as a slightly lower band than the 18 kDa LC3-I band as a result of the greater hydrophobicity of LC3-II.
However, in some instances, the LC3-I and LC3-II bands are incompletely resolved, which complicates analysis. Also, even when LC3-I and LC3-II are adequately separated on an immunoblot, changes in the relative ratios of the isoforms may not be directly proportional to autophagosome quantity, due to differential immunoreactivity of the isoforms. Merck’s LC3-II Enrichment Kit (Western Blot) enables sensitive and accurate quantification of autophagosome density by utilizing a selective permeabilization procedure that removes cytosolic LC3-I and retains autophagosome-bound LC3-II. This procedure reveals quantities of LC3-II, without interference from LC3-I, by Western blotting analysis.
However, in some instances, the LC3-I and LC3-II bands are incompletely resolved, which complicates analysis. Also, even when LC3-I and LC3-II are adequately separated on an immunoblot, changes in the relative ratios of the isoforms may not be directly proportional to autophagosome quantity, due to differential immunoreactivity of the isoforms.
Merck’s LC3-II Enrichment Kit (Western Blot) enables sensitive and accurate quantification of autophagosome density by utilizing a selective permeabilization procedure that removes cytosolic LC3-I and retains autophagosome-bound LC3-II. This procedure reveals quantities of LC3-II, without interference from LC3-I, by Western blotting analysis.